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ABSTRACT 
Pituitary adenomas account for roughly 12% of all intracranial tumours and are treated either 
surgically or medically. Due to the prevalence, there have been many articles focusing on their 
treatment. Recently, a few studies have been published suggesting a link between pituitary 
tumours, their treatment and cognitive dysfunction. These articles challenge the texts put forward 
to date, texts that demarcate adenoma treatment effects to the realm of the physicaL The 
mechanism(s) behind these supposed deficits have not yet been identified, largely because of 
problematic research designs and sampling. In the South African context, practitioners tend to 
encounter a greater proportion of macroadenomas than developed countries. Working on the 
assumption that the effects of adenomas are magnified in macroadenoma patients, the South 
African situation provides a base of extreme cases in which any potential dysfunction has the 
best chance to declare itself. This is particularly valuable given the controversy surrounding the 
presence of these cognitive deficits. 
The aims of the present study were to evaluate the neuropsychological functioning of patients 
with pituitary macroadenomas as well as to compare the neuropsychological effects of the two 
primary modes of treatment: transsphenoidal surgery supplemented with radiotherapy, and 
medication. 40 participants aged 18 - 70 were recruited. 10 patients with newly diagnosed 
macroadenomas were recruited prior to treatment, 10 patients had undergone transsphenoidal 
surgery followed by radiotherapy and 10 patients were being medicated with dopamine agonists. 
10 controls were used as a comparative base. Each participant was assessed with a 
neurocognitive test battery. Analysis of variance was used to evaluate macroadenoma patients 
against controls as well as to comparc the performance of the two distinct treatment groups. 
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Results showed a significant difference between the four groups on only one neuropsychological 
measure, a result interpreted as indicative of type 1 error. The study suggests that neither 
adenomas themselves nor their treatment impact on cognitive functioning. 
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INTRODUCTION 
The pituitary gland lies at the base of the brain, in the pituitary fossa of the sphenoid bone, 
covered by the diaphragma sellae and just below the optic chiasma. It is bordered on each side by 
the cavernous sinuses. Pituitary tumours are common, accounting for roughly 12% of all 
intracranial tumours, and the great majority are benign. Adenomas are classified by size: the 
largest, those greater than lOmm in diameter, are labeled macroadenomas. 
In the South African context, practitioners tend to encounter a greater proportion of 
macro adenomas than in developed countries. This is, in large part, due to a lack of resources in 
the South African population. Patients often cannot afford transportation to day hospitals. Many 
are members of the casual wage system, where payment per hour means they cannot take time 
off to visit a doctor. Moreover, the pervasive lack of education results in low disease awareness, 
meaning that presentation in general is lower than one would expect in more educated areas. 
Finally, there are insufficient medical resources in the country - low doctor-per-citizen ratios, 
widely spaced major hospitals and insufficient equipment. All of these factors lead to later 
diagnosis in the disease process. Working on the assumption that the effects of adenomas are 
magnified in macroadenoma patients, the South African situation provides an ideal (albeit 
unfortunate) base of extreme cases in which any potential dysfunction has the best chance to 
declare itself. This is particularly valuable given the controversy surrounding the presence of 
these cognitive deficits. Un
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THE PITUITARY GLAND 
The pituitary gland is a vital component of the endocrine system. It receives input from the 
hypothalamus and releases hormones, at the same time stimulating hormone secretion in the 
thyroid, adrenals and gonads. Pituitary adenomas - essentially a disruption of the gland itself and 
therefore its properties - present with any combination of hormone overproduction or 
suppression, with hypersecretion being the most common outcome. 
The anterior pituitary is associated with the production of six hormones, namely growth hormone 
(GH), Prolactin (PRL), Follicle-stimulating hormone (FSH), Luteinizing hormone (LH), 
Adrenocorticotropin (ACTH) and Thyroid-stimulating hormone (TSH). These hormones 
stimulate target organs at a distance from the pituitary. The nomenclature of pituitary adenomas 
is based on the premise that their clinical effects derive from endocrine imbalance, rather than 
their various histopathologies. Therefore pituitary adenomas are classified according to the 
particular hormone that they secrete in excess. Of the endocrinologically active adenomas, 
prolactinomas are the most common, making up 55% of all secreting adenomas. They are caused 
by the interruption of the hypothalamic inhibitory hormone, dopamine, which leads to excess 
secretion ofPRL. GH-secreting adenomas make up 27% of endocrinologic ally active adenomas 
and lead to acromegaly in adults, while dual-secreting or mixed adenomas, secreting both PRL 
and GH, account for a further 12%. ACTH-secreting adenomas make up 4% of secreting 
adenomas and lead to steroid excess. Gonadotrophin-secreting adenomas, involving excess 
production of FSH and! or LH, make up the last 1 - 2% of endocrinologically active adenomas. 
TSH-secreting adenomas do occur but are rare (Johnson and Lightman, 1996). Adenomas that 
are endocrinologic ally inactive are formally classified as non-functional. Because they may 
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later in the disease process than secreting tumours, making them the most common type of 
macroadenoma (Yeh and Chen, 1997). 
Adenomas can also cause hypopituitarism in two ways. First, the blood-flow between the 
hypothalamus and the pituitary gland (which normally contains hypothalamic releasing 
hormones which act on the pituitary) can be obstructed by the enlarging mass. Second, normal 
anterior pituitary tissue can be destroyed by the invading tumour. The latter is particularly 
common in non-functional adenomas (Leavens, 1973). 
9 
Aside from endocrine significance, the central location of the pituitary gland leads tumours of 
that region to exert mass effect on significant surrounding structures. The optic chiasma sits 
directly above the pituitary fossa and as the adenoma expands upwards and out of the 
diaphragma sella it tends to compress the chiasma. Because of this, adenoma patients frequently 
present with reduced visual acuity and visual field defects, most notably bitemporal hemianopia 
(Yeh & Chen, 1997). With continued growth superiorly, adenomas may invade the third 
ventricle and the thalamus. An adenoma that spreads superiorly and anteriorly may compress the 
medial surface of the frontal lobes. Growth in an inferior direction can lead to invasion of the 
sphenoidal sinuses. Lateral spreading can involve compression of the cavernous sinuses and 
temporal lobes (Powell and Lightman, 1996). 
Treatment options for pituitary macroadenoma patients vary, depending on the type and level of 
hormone secretion, tumour size, patient age, patient's past medical history, and the subjective 
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preference of both the clinician and patient. Since the introduction of the intraoperative 
microscope, and the development of newer antibiotics, surgical management of pituitary tumours 
has changed from the trans frontal craniotomy to the now-preferred transsphenoidal procedure. 
The sphenoidal sinus route lends easy access to the pituitary gland and poses less threat to the 
optic chiasma. While surgery does sometimes achieve complete tumour removal, in the case of 
macroadenomas in particular, cure based on surgery alone is very rare. In general, surgery aims 
to debulk the mass, thereby decompressing the chiasma and other local structures. Such partial 
removal of an adenoma usually improves vision considerably and can achieve what is normally a 
temporary endocrine cure (Powell, 1996). Repeat trans sphenoidal surgery is common because of 
either tumour regrowth or insufficient tumour removal at the first procedure. The risk of 
mortality associated with neurosurgery for adenomas, although low, is regarded as its primary 
disadvantage. In 1996, Powell and Lightman reported that defense unions in the United Kingdom 
have approximately one case per year passing through the medicolegal system. 
As a result of the surgical aim of debulking rather than complete ablation, transsphenoidal 
procedures are most often supplemented with radiotherapy. External radiotherapy is practiced, as 
are more focal techniques like proton beam radiation. External radiation uses photon energies, 
delivering dose of between 45 and 54 Gy over four to six weeks (Yeh & Chen, 1997). Rivaling 
conventional radiotherapy, proton beam radiation uses focused beams rather than generalized 
radiation. Heavy particles are delivered directly to the adenoma, sparing normal pituitary tissue 
and adjacent structures such as the optic chiasma, the hypothalamus and temporal lobes (Shalet 
and O'Halloran, 1996). This type of intense irradiation uses high-energy particles to overcome 
the pituitary gland's relative insensitivity to radiation, without administering large doses to a 
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broad area of vulnerable tissue (Lawrence et a1., 1973). However, response to radiation tends to 
be slow and its benefits may take considerable time to be realized (Yeh & Chen, 1997). 
Conventional radiation therapy in adenoma patients is associated with a risk of hypothalamic and 
optic chiasmal injury (Atkinson et aI., 1979), and can injure the frontal and temporal lobe tissue 
(Sheline, Warra and Smith, 1980). There is also a small risk of radiation necrosis and radiation-
induced seizures (Yeh & Chen, 1997). 
Postoperatively, the incidence of hypopituitarism is said to be related to tumour size at surgery. 
For macroadenomas, the incidence is reported at 30%. Similarly, radiation can lead to 
hypopituitarism, with an incidence of up to 30% (Yeh & Chen, 1997). In a follow-up study 
undertaking endocrine evaluation of nineteen pituitary adenoma patients five to ten years after 
surgery and radiotherapy, Muhr, Bergstrom, Enoksson, Hugosson and Lundberg (1980) found 17 
had thyroid insufficiency, 16 gonadal insufficiency and 12 adrenal insufficiency. 
Certain pharmacological agents have been shown to decrease tumour size, suppress tumour 
regrowth and inhibit hormone secretion. This type of drug therapy is a much more recent 
advance in adenoma treatment than either surgery or radiotherapy. Dopamine agonists like 
bromocriptine have been in use since the 1970's and most clinicians now consider them to be the 
optimal treatment for prolactinomas, choosing to medicate rather than operate (Johnson & 
Lightman, 1996). Dopamine begins to inhibit prolactin secretion within one hour of 
administration, induces prolactinoma shrinkage, reverses visual abnormalities and restores 
normal pituitary functions (Yeh & Chen, 1997). A small number of authorities do however 
continue to uphold surgery as first-line treatment for macroprolactinomas. The rationale of the 
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pro-surgery camp is that surgery has the potential - however small - to act as a once-off cure, 
whereas dopamine agonist treatment is invariably life-long. In those cases where withdrawal 
from medication has been recommended, reports indicate a high incidence of tumour regrowth, 
increase in prolactin levels and recurrence of original symptoms (Lightman and Powell, 1996). 
Some GH-secreting tumours are also sensitive to dopamine agonists, as the drug appears to cause 
partial inhibition of growth hormone release. However, this regulation is usually temporary 
(Kontogeorgos, 1993). Pituitary-dependent Cushing's disease has been reported to respond to 
bromocriptine in individual cases (Johnson & Lightman, 1996; Yeh & Chen, 1997). Finally, 
there have been some reports of non-secreting adenoma shrinkage in response to bromocriptine, 
although pharmacological treatment tends not to be advocated for these adenomas as they tend to 
present as exceptionally large (Yeh & Chen, 1997). The dopamine analogue of first choice is 
generally bromocriptine, but pergolide, carbergoline and quinagolide are used as alternatives or 
in cases where bromocriptine is not tolerated (South African Medicines Formulary [SAMF], 
2(01). 
More recently, somatostatin analogues have been used successfully in the treatment of 
acromegaly. Somatostatin, a 14-amino acid peptide, leads to the suppression of growth hormone 
release from the pituitary gland and the suppression of growth hormone releasing hormone from 
the hypothalamus (Yeh & Chen, 1997). Kontogeorgos (1993) suggests that somatostatin also 
blocks the release of prolactin and TSH. Specifically, the synthetic compounds ocreotide and 
somatuline have been used in acromegalic patients resistant to dopamine agonists, unsuitable for 
surgery or with continued high growth hormone levels following surgery and! or radiotherapy 
(Johnson & Lightman, 1996). Somatostatin analogue therapy has some major disadvantages, 
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among them the need for frequent injections and the high cost involved. Long-term therapy 
appears not to effect tumour shrinkage (Kontogeorgos, 1993). 
As far as Cushing's patients are concerned, the most common medical alternative to surgery has 
been metyrapone, with mitotane and ketoconozole following closely. However, the side effects 
associated with these treatments, such as virilism, hypercholesterolaemia and liver damage, have 
limited wide usage. On a case by case basis, certain other agents have been used and reported 
successful, namely cyproheptadine (a serotonin antagonist) and sodium valproate (a GABA 
transaminase inhibitor). Finally, as mentioned earlier, bromocriptine has been reported as 
occasionally successful in ACTH-secreting adenomas (Johnson & Lightman, 1996). 
Due to the prevalence of pituitary adenomas, there have been many articles focusing on their 
treatment. Every possible aspect of adenoma intervention has been described in detail through 
extensive case reports. Since the publication of the first adenoma surgery texts dating as far back 
as the 1930's, there has been no mention of cognitive dysfunction resulting from treatment. 
Representative of the entire genre of pituitary intervention texts is a paper on the complications 
associated with transsphenoidal resection of pituitary adenomas by Ciric, Ragin, Baumgartner 
and Pierce (1997) in which the results of a large-scale national survey of neurosurgeons, an 
extensive review of the literature and an experiential outline are presented. In none of these 
sections is there even a subtle reference to possible cognitive effects of these masses. Un
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NEW CLAIMS REGARDING COGNITIVE DEFICITS 
Recently, a few studies have been published suggesting a link between pituitary tumours, their 
treatment and cognitive dysfunction. These four articles challenge the many texts put forward to 
date, texts that demarcate adenoma treatment effects to the realm of the physical. Whilst the 
claims made by the recent studies are engaging, the work needs to be interpreted with caution for 
three important reasons, not least being their novelty. Given the considerable attention received 
by the topic of intervention for pituitary adenomas, it would be surprising should it transpire that 
all prior, far-ranging descriptions had overlooked such an effect. Nonetheless, cognitive 
neuroscience is a particularly burgeoning field, given to unexpected findings, so this concern 
does not entirely negate the possibility of the validity of the new work. It is also true that the 
subject of cognition has, for the most part, been routinely disregarded by medical research in the 
past, and that science's cognizance of the area of late is conducive to fresh discoveries. The 
second caution, which should be applied to a review of the recent studies, involves a series of 
intra-article methodological issues, some of which impinge on the validity of the tindings. The 
third and final consideration is that the new studies, while grouped together here as a 
homogeneous thesis of cognitive effects of adenoma treatment, do not reach consensus on certain 
basic points as regards the nature of the very cognitive deficits they describe as well as their 
basis(e). In what follows, the last two considerations will be expanded upon in relation to the 
new studies. 
Grattan-Smith, Morris, Shores, Batchelor and Sparks (1992) assessed memory and executive 
functions in 65 patients who had been diagnosed with a pituitary tumour. The 65 patients were 
made up of two groups - 38 patients who had undergone radiotherapy and 27 who had not been 
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treated with radiotherapy. Both groups were compared with a control group made up of patients 
with chronic illness not involving the cerebrum. The study found that collectively, pituitary 
patients performed worse than controls in tests of visual and verbal memory as well as executive 
functions. There was however no difference between the radiotherapy and non-radiotherapy 
groups on any of the neuropsychological tests administered, nor a correlation between 
neuropsychological performance and surgical procedure. 
Further analysis of the research design employed in the study reveals several critical 
methodological problems, which threaten the validity of the aforementioned findings. The most 
pressing issues can be ascribed to erroneous sampling. First off is the exclusion from the 
radiotherapy group of four cases of confirmed delayed radiation damage, one of the patients 
having been diagnosed with dementia. The reason for their exclusion was death in one case and 
chiasmal damage in the other three. While the practicalities responsible for the exclusion are 
plain and inflexible, the effects thereof are clear. Elimination of those patients affected by the 
most predictable form of damage incurred by radiation in an investigation designed to assess the 
damage associated with radiation would certainly have skewed the radiation group scores in a 
positive direction. The second criticism is the heterogeneity of the 'non-radiotherapy' group. Of 
the 27 patients making up the group, seven were assessed during investigations prior to 
intervention while the remainder had been treated with surgery and! or medication. Because of 
the group's diversity, the authors were unable to reasonably attribute the cognitive impairments 
found to any particular variable such as the tumour itself or either of the forms of treatment 
received by members of the group. The third issue is that the radiotherapy and non-radiotherapy 
groups were not matched in terms of diseased type. For instance, the radiotherapy group 
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contained eight out of a total of 38 patients with Cushing's syndrome (21 %), whereas the non-
radiotherapy group included only two out of a total of 27 patients (7%). Finally, the patient 
sample included a number of participants with medical conditions already associated with 
cognitive dysfunction. Specifically, two reported a history of alcohol abuse, one had complex 
partial seizures and another had had a previous stroke. The paper does state that these conditions 
'were also considered' (1992: 627) as possible contributors to the picture of cognitive 
dysfunction, but does not elaborate, and then goes on to attribute the cognitive deficits found to 
pituitary related factors only. 
A further comment on the intra-article design is that the set of tests purported to assess executive 
functioning is altogether incomplete. The domain of executive functioning is particularly broad, 
and the three tests used to measure its presentation are clearly not exhaustive. Participant 
performance on certain key aspects of functioning, most notably abstraction and inhibition, was 
not established. One could argue that inhibition was assessed to some extent through COW AT 
and Trail Making B, but because the study design extracted only single measures from these 
tests, any disinhibition would have been assimilated into the word generation and flexibility 
scores of the respective tests, rather than being evident in its own right. A standard test of 
abstraction such as the Twenty Questions Task as well as some form of inhibition assessment 
like the Stroop Neuropsychological Screening Test (Trennery, Crosson, Deboe & Leber, 1989) 
would have completed the battery. Furthermore, despite the fact that only one of the three tests of 
executive functioning yielded a significant difference between pituitary patients and controls 
(Trails Making B), the conclusion presented by the paper is that executive functioning - that wide 
range of behaviours we know to encompass initiative, planning, self-verification, abstraction, 
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mental flexibility, reasoning and social-appropriateness in the most fluid manner of all cognitive 
functioning - was impaired. 
In the second study, Peace, Orme, Thompson, Padayatty, Ellis and Belchetz (1997) assessed 
cognition and mood in 36 patients who had been treated for pituitary tumours and compared 
them with 36 healthy controls. Neuropsychological tests of memory and executive functions as 
well as standard self-report measures were used to assess cognition and mood respectively. 
As with the first reported study, the patient group showed impaired memory and executive 
functions as compared with controls. Also in accordance with that study, there were no 
significant differences between patients who had had radiotherapy and those who had not. 
However, the finding that is incongruous with the first study is that the cognitive deficits were 
discovered to be related to surgery, whereas Grattan-Smith et al. (1992) found no correlation 
between neuropsychological performance and presence of surgery. Although surgery was 
implicated here, there was no difference found in a comparison of patients treated with 
transsphenoidal surgery and transfrontal surgery. The mood assessment revealed no difference 
between pituitary patients and controls. 
Again, it is difficult to draw conclusions from this study due to the heterogeneity of the patient 
group. Of the 36 patients making up the group, 27 had had surgery (13 transsphenoidal and 14 
transfrontal), and of this 27, 18 had had radiotherapy. Another two patients were receiving 
bromocriptine. While the authors state that another five patients were not receiving medication at 
the time of assessment, they do not disclose whether these patients had received medication in 
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the past or if they were still awaiting treatment. As for the remaining two patients, no mention is 
made of their treatment status. While the effects of surgery and radiation are examined through 
the formation of subgroups at the analysis stage, the neuropsychological consequences of 
medication are never considered, nor are the effects of the tumour itself. Once again, the 
diversity of the participant group meant that the paper was unable to attribute the deficits to any 
particular aspect of pituitary disease. In addition, while the four tests of executive functions 
constitute a list that is more inclusive than the first study and therefore a better representation of 
the broad domain of executive functioning, the key function of abstraction was also not 
accounted for in the assessment. As with the first study, it would have been prudent to use a 
standard test of abstraction such as the Twenty Questions Task. 
The third study is a paper by Guinan, Lowy, Stanhope, Lewis and Kopelman (1998) who 
document two case studies of patients with pituitary adenomas who had received transsphenoidal 
surgery, one with and one without radiotherapy. In the same paper, the authors describe the 
findings from a neuropsychological investigation of 90 patients who had been treated for a 
pituitary adenoma as compared with 19 healthy controls. The patient sample was subdivided into 
four groups: those who had received transfrontal surgery with radiotherapy, transsphenoidal 
surgery with or without radiotherapy, radiotherapy only and a bromocriptine therapy group. In 
the two post-surgery case studies presented, memory impairments are described. This impression 
is in line with the previous study's finding that neuropsychological performance is related to 
presence of surgery but contradicts that of the Grattan-Smith et a1. (1992) paper. In addition, the 
more severely affected patient had received radiotherapy which opposes the findings of both 
previous studies. The retrospective group study demonstrated significant memory deficits in the 
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patient group as compared with controls, which supports similar findings in both previous 
studies. However, unlike the previous publications, executive functions were found to be intact. 
Memory impairment was evident in the surgery groups, a finding compatible with the Peace et 
al. (1997) paper but opposing that of Grattan-Smith et al. (1992). Deficits were seen in the 
radiotherapy only treatment group relative to controls, a finding which is irreconcilable with both 
previous studies' conclusion that radiotherapy and neuropsychological performance are 
unrelated. Finally, while the bromocriptine group did perform significantly worse than controls, 
the degree of impairment was less than that of surgical and radiotherapy patients. 
In the fourth study, Peace, Orme, Padayatty, Godfrey and Belchetz (1998) performed memory 
and executive function assessments on three groups of 23 pituitary patients who had been treated 
with trans frontal surgery, trans sphenoidal surgery and medication respectively and compared 
them with healthy controls. Consistent with the first two reports but conflicting with the third, 
the study found impairments in both memory and executive functions. In addition, unlike the 
Grattan-Smith et al. (1992) paper but in line with the more recent publications, the surgical 
groups were found to be more impaired than the non-surgical patients. Furthermore, whereas 
Peace et al. (1997) observed no difference in neuropsychological profile between transfrontal 
and transsphenoidal patients, this investigation reports that transfrontal patients were more 
severely impaired than trans sphenoidal. Finally, unlike Guinan et al. (1998), but supporting the 
findings of the first two publications, there was no significant difference between those who had 
radiotherapy and those who had not. Methodologically, the same battery of tests was used as in 
the Peace et al. (1997) study; consequently the same criticism applies. The important executive 
function of abstraction was not investigated in the assessment. As with that study, it would have 
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been valuable to add a standard test of abstraction such as the Twenty Questions Task to the 
executive battery. 
In sum then, the four central studies implicate pituitary adenomas and their treatment in 
cognitive dysfunction. Aside from this general idea, the articles are divided on much of the 
specifics, principally the nature of the deficits involved and their cause. The mechanism(s) 
behind these supposed deficits have not yet been identified, largely because of problematic 
research designs and sampling. Whether impairment is due to compression of adjacent structures, 
disruption of pathways and! or hormonal imbalance resulting from the tumour itself, or whether 
surgical, radiological and! or medical intervention is responsible, is still unclear. 
Of substantial consequence is the fact that in no study were adenoma patients set up as an 
independent sample group prior to treatment. Instead, they formed part of various composite 
groups. The reason for this design fault is the persistent focus on the effects of adenoma 
treatment, without regard for a systematic investigation into those of the adenoma itself. The 
result of this error of attention is that where cognitive dysfunction was found, at the stage of 
interpretation the articles have been powerless to attribute the deficits to any specific mechanism. 
In all likelihood, the rationale behind this intervention-focussed research is that it allowed for 
patients to be assessment post rather than prior to intervention. This is in the context of the 
relative speed with which intervention is carried out in first world countries, where the research 
has been conducted and published. Sadly in a country like South Africa where poverty is rife and 
state hospitals are under-resourced, patients may wait as long as six months before being treated. 
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This allows sufticient opportunity for full neuropsychological asscssmcnt prior to intervention, 
meaning that the effects of the tumour itself can be separated from those of its treatment. 
PITUITARY AND COGNITION 
Aside from the four specific investigations into the cognitive effects of the treatment of pituitary 
tumours, there are three broad areas of work also related to the topic of adenomas: a) theses on 
the cognitive effects of adenomas, based on theory rather than systematic investigation, b) 
research into the effects of surgical, radiological and medical intervention in which the 
dependent measures do not include neuropsychological variables and c) investigations into 
individual hormonal changes and neuropsychological effects. 
Theory-based Theses on the Cognitive Effects of Adenomas 
To date, there has been no study published that systematically investigated the cognitive effects 
of a range of pituitary adenomas prior to treatment. What has been disseminated are a small 
number of academic texts, alleging a link between adenomas and neuropsychological deficits, 
with no explanation as to the neural basis for or mechanism behind these assertions. Luria 
(1976), for instance, explains that gross changes of consciousness, severe changes in memory 
and disorders of interest or emotions can occur with pituitary tumours. Randall (1982: 16) reports 
"changes in intellect and personality". Lishman (1987) lists the following disturbances: amnesic 
states, emotional instability, apathy, paranoia, and general deterioration of personality. Aside 
from the fact that they are conceptual rather than investigative, what these texts have in common 
is that they offer a particularly nebulous account of cognitive presentation. 
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The Effects of Surgical, Radiological and Medical Intervention 
As discussed, there is no shortage of publications focussing on surgical, radiological and medical 
treatment of adenomas. Despite this, and the reason for the deliberation about the new studies, is 
that one would be hard-pressed to find evidence of research in which cognition and! or mood was 
investigated in relation to pituitary intervention. Hence, interest in possible neuropsychological 
effects of adenoma treatment requires a certain level of awareness of the various associations 
between neuroanatomical systems and cognition, and an application of this knowledge to texts 
with an exclusively neurophysiological focus. 
With respect to the effects of pituitary surgery, Ciric et a1. (1997) surveyed 958 neurosurgeons 
regarding the frequency and type of complications associated with the transsphenoidal 
procedure. The five most common complications were related to anesthesia, carotid artery injury, 
central nervous system injury, hemorrhage/ swelling of residual tumour and loss of vision. Of 
relevance to cognition, are the carotid artery injuries and hypothalamic injuries, occurring with 
an incidence of 1 to 2%. Due to the fact that the carotid arteries supply most of the cerebral 
hemispheres, through the anterior cerebral and middle cerebral arteries, carotid injury could 
potentially lead to any form of cognitive dysfunction, with the exception of the agnosias. In that 
the hypothalamus is implicated in behaviour patterns relating to physical protection, such as rage 
and fear reactions, mood states may be affected by hypothalamic lesions (Lezak, 1995). 
In a follow-up study of 19 patients five to ten years after transfrontal surgery for an adenoma, 
Muhr et a1. (1980) noted postoperative atrophic changes in three patients. The changes were in 
the frontal lobes, manifesting as a combination of reduced attenuation in the parenchyma and a 
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widened hom of the lateral ventricle on the ipsilateral side as that on which the craniotomy had 
been performed. Frontal lobe atrophy can lead to executive dysfunction, with characteristic 
deficits in such functions as attention, planning, inhibition and abstraction. 
As to the effects of radiotherapy as treatment for brain tumours, Victor and Ropper (2001) 
outline three identifiable syndromes, differentiated from one another by time of onset and 
symptomatology: acute, early delayed and late delayed reactions. Of significance to cognition is 
late delayed injury. The processes involved are necrosis, spongiform changes in white matter, 
atrophy and demyelination. Symptoms tend to surface three months to several years following 
radiotherapy and can resemble those of either an enlarging mass or a progressive dementia. 
Patients are described as mentally slowed and slightly disinhibited. Focal or generalized seizures 
can occur. 
Kramer (1968) reviewed the literature of published cases of necrosis following radiotherapy to 
the pituitary region and concluded that injury tends to occur with administration of excessively 
high doses (between 7,700 and 43,200 rads). "(Brain necrosis) must be considered quite rare 
when an acceptable dose is given in a single course of treatment spread over an adequate amount 
of time" (1968: 310). 
As regards the effects of dopamine agonists on cognition, McDowell, Whyte and D'esposito 
(1998) maintain that dopamine is an important neurotransmitter in terms of executive 
functioning. Patients with Parkinson's disease, characterized by depleted dopamine levels, 
exhibit cognitive impairment attributable to executive dysfunction. When treated with 
Un
ive
rsi
ty 
of 
Ca
pe
 To
w
Page 24 
dopaminergic medication, these patients have been shown to improve on a range of executive 
function tasks, such as the Wisconsin Card Sorting Task, a verbal fluency task and the Tower of 
London task. The authors examined the effects of low-dose bromocriptine on cognitive 
processes in 24 traumatic brain injury patients. Each patient was assessed twice: once on 2.5 mg 
bromocriptine and once on a placebo. The authors found bromocriptine to improve performance 
on tasks of executive function, specifically dual-task performance, inhibition, verbal fluency and 
perseveration. There was no improvement in tasks measuring cognitive processes outside of 
executive functions. The authors concluded that bromocriptine has a positive effect on specific 
executive processes. The fact that only executive tasks were improved relative to other functions 
was taken to mean that the effect was not attributable to increased arousal, attention or response 
speed. As to the neural basis of the improvement, McDowell and colleagues postulated that 
direct prefrontal D2 receptor activity (some studies have shown stratification of D2 receptors to 
layer V of the prefrontal cortex) or the activity of D2 receptors in the striatum (where most D2 
receptors are situated) which activate the prefrontal cortex through mesocortical dopaminergic 
loops might be responsible. 
Administration of bromocriptine has been associated with psychotic reactions, namely 
hallucinations and delusions, but the reported incidence is low. These reactions are said to occur 
with relatively low doses and remit with cessation of medication (Meyers, 1998). 
Investigations into Individual Hormonal Changes and their Neuropsychological Effects 
Pituitary adenoma symptomatology has been so well documented that there is near consensus 
regarding the list of associated features. The high incidence of these tumours has meant that even 
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introductory neurology, neurosurgery and endocrinology texts have included a section on 
presentation of adenomas. Throughout the countless medical texts, both introductory and 
advanced, the manifestations of pituitary adenomas have almost always been profiled as almost 
entirely corporeal. The biggest exception has been the attention given to the psychiatric 
manifestations of Cushing's syndrome specifically. Conventionally, prolactinomas are reported 
to present with amenorrhea and galactorrhea in women and loss of libido and sexual impotence 
in men, growth hormone-secreting adenomas with morphological features and ACTH-secreting 
adenomas with obesity, hypertension, diabetes mellitus, osteoporosis, amenorrhea, psyehosis and 
depression. Non-functioning adenomas are associated with visual field defects and headaches. 
These are the established presentations, available on the pages of every standard textbook on the 
subject. The absence of neuropsychological data in most pituitary texts reflects the prevailing 
opinion amongst medical professionals that pituitary tumours do not affect cognition or mood. 
That said, if we look to the individual hormonal changes associated with pituitary tumours, there 
have been some publications reporting associations between excess and! or deficient hormone 
production and cognitive dysfunction. It is to these specific papers that we now tum. 
Neuropsychological Effects of Prolactin 
Based on a review of pretreatment physician notes of 16 men with prolactinomas, Cohen, 
Greenberg and Murray (1984) describe the emergence of a specific symptom constellation, one 
aspect of which they term 'apathy'. For the purposes of the study, the authors define apathy as 
'fatigue, lethargy and! or loss of interest in daily activities' (1984: 926). While it is clear from the 
objectives and conclusion of the paper that the intent of the study was to identifY and 
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communicate psychiatric manifestations of hyperprolactinemia, the fact that such a broad 
definition of apathy was used, meant that non-psychiatric causes of fatigue and lethargy would 
also have been categorized as 'apathy'. A further methodological point is that data was 
accumulated from patient charts that had been completed over a ten year period prior to the 
outset of the study. The disadvantage of this research design is its reliance on numerous 
clinicians who mayor may not have been equipped to assess - or been mindful of - psychiatric 
functioning. 
Neuropsychological Effects of Growth Hormone 
Margo (1981) reports a case of psychiatric complications associated with acromegaly. The 
patient in question had a pituitary tumour with elevated growth hormone levels. She also 
suffered from chronic depressive illness. Following radiation therapy for the adenoma, she 
became significantly less depressed. The paper reasons that while the precise relationship 
between the two diseases for the patient is unresolved, the possibility exists that the growth 
hormone abnormality may have been responsible for the patient's depression. 
Several articles have been published with reference to quality of life in patients with GR 
deficiency (Deijen, de Boer, Blok and van der Veen, 1996; McGauley, 1989; Peace, Orme, 
Sebastion et aI., 1997; Rosen, Wiren, Wilhelmsen, Wiklund and Bengtssen, 1994). Growth 
hormone deficient children have been reported to be psychologically immature and to display 
deviant personality development while deficient adults have been reported to be more likely to 
be unemployed and single (Deijen et aI., 1996). Using self-report measures, some authors have 
found that those with deficient GR tend to report poorer quality of life than control subjects 
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(McGauley, 1989; Rosen et aI., 1994). Meyers (1998) notes that patients with affective disorders 
often have abnormal growth hormone secretion, thereby implicating the hormone in mental 
illness processes. In contrast to these reports, Deijen et a1. (1996) administered three 
questionnaires exploring various aspects of mood and psychological state to 17 patients with 
isolated growth hormone deficiency as well as 41 healthy participants and found no differences 
with respect to depression or anxiety. 
There is evidence associating GH deficiency with memory loss. Deijen et a1. (1996) evaluated 
the cognitive performance of 31 men with multiple pituitary hormone deficiencies (including GH 
deficiency) as well as 17 men with isolated growth hormone deficiency and found both to exhibit 
subnormal memory performance compared with healthy controls on tests of list-learning and 
paired associates. The authors concluded that poor memory in both groups was related to growth 
hormone deficiency. Although no specific mechanism has been identified for memory loss in 
growth hormone deficient adults, it is worth noting that high density growth hormone binding 
sites have been demonstrated in brain regions implicated in learning, specifically, the 
hippocampus (Burman et aI., 1998). 
Neuropsychological Effects of A eTR 
The primary topic that has received attention in the literature is the link between ACTH-
producing adenomas and psychiatric disturbances, most notably depression (Dorn, Burgess, 
Dubbert et aI., 1995). In addition, Tran and Elias (2003) report that generalized anxiety disorder 
occurs in 79% of Cushing's patients. Finally, emotional lability and even frank psychosis can 
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occur (Yeh & Chen, 1997). Weitzner (1998) notes that psychopathology may even predate the 
onset of the physiological changes associated with Cushing's disease. 
Dom et al. (1995) examined 33 patients with Cushing's syndrome, the majority of which (n = 29) 
had pituitary adenomas. These patients had higher levels of depression and anxiety compared 
with healthy controls. 66.7% of patients met criteria for a psychiatric diagnosis. The most 
common diagnosis was major depressive disorder, with other diagnoses including hypomania, 
panic and alcohol or drug abuse. The authors concluded that patients with Cushing's syndrome 
exhibit significant psychopathology. 
Starkman and Schteingart (1981) examined 35 patients with Cushing's syndrome prior to 
treatment. Of the group, 26 had a pituitary tumour, while the rest were made up of thymomas, 
adrenal adenomas and adrenal carcinomas. Based on semi-structured interviews, 86% of the 
sample was identified as experiencing increased irritability and anger, 77% depressed mood 
(ranging from short periods of sadness to suicide attempts), and 66% generalized anxiety. With 
regard to cognition, 83% of the sample was described as subjectively experiencing memory 
difficulties: these patients forgot appointments, lost objects and had difficulty remembering 
names. On testing, 31 % of patients could not recall three cities after 15 minutes. 66% reported 
impaired concentration, manifesting as distractibility. In accordance with this, 51 % of 
participants were classified as abnormal on the Mental Status Examination's Serial 7 subtraction 
task. These cognitive dysfunctions were in the context of normal orientation and consciousness. 
There was an association between both ACTH and cortisol levels and the severity of 
neuropsychological deficits. 
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As far as the neurophysiological process relating to these cognitive deficits is concerned, the 
adrenal cortex secretes honnones collectively known as corticosteroids in response to the release 
of ACTH by the anterior pituitary. Hypersecretion of ACTH due to a pituitary adenoma leads to 
increased corticosteroid secretion (Erlanger, Kutner, and Jacobs, 1999). Prolonged exposure to 
high levels of corticosteroids has been reported to adversely affect memory (Keenan, Jacobson, 
Soleymani, Mayes, Stress and Yaldoo, 1996) and the mechanism responsible has been identified 
as the remodeling of hippocampal physiology (Brown, Rush & McEwen, 1999). Excess 
corticosteroids are said to accelerate pathologic changes in the hippocampus, a site essential to 
memory processes (Keenan et aI., 1996). 
As far as exogenously administered cortisol (such as cortisone or prednisone) is concerned, the 
link between high doses (more than 40mg per day) and acute psychiatric reactions has been well 
established. Episodes generally involve psychoses and or euphoria (Starkman & Schteingart, 
1981). Bunnan et al. (1995) explain that many patients with hypodrenalism secondary to 
pituitary disease are given a standard dose of corticosteroids despite the fact that a lower dose 
would nonnally be sufficient. They reason that there is inter-individual sensitivity to 
corticosteroids and that the administration of conventionally high doses might have negative 
emotional effects. 
In a paper examining the effects of both acute and chronic prednisone treatment on memory, 
Keenan et al. (1996) assessed memory functions in 25 patients with systemic disease (without 
CNS involvement) and compared the results with matched controls. Patients were receiving 
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doses of between 5 and 40 mg daily (mean 16.4mg) and had been on stable treatment for at least 
one year. Memory performance in the prednisone patients was significantly worse than that of 
controls. In a second investigation published within the same article, the authors examined the 
acute effects of prednisone on memory across three months of therapy. Prednisone dosage 
ranged from 5 to 80mg. This prospective design entailed the assessment of seven patients three 
times: one week prior to, one week after and twelve weeks after prednisone treatment. There was 
a consistent decrease in memory performance across time. The authors concluded that both acute 
and chronic prednisone treatment can adversely affect memory. 
As to whether these findings relating to exogenous steroids are relevant to patients with 
spontaneously high cortisol levels, Starkman and Schteingart (1981) caution that the level of 
circulating cortisol in Cushing's patients is not as high as the equivalent amount of steroids 
administered with hormone replacement therapy. Moreover, Cushing's patients are exposed to 
sustained elevated cortisol levels rather than acute changes associated with steroid 
administration. 
With respect to the effects of reduced ACTH on cognition, in Deijen et a1. (1996)'s assessment of 
31 men with multiple pituitary hormone deficiencies subnormal perceptual-motors perfonnance 
was found. Since a substantial number of the patients were ACTH deficient, the authors 
attributed the low scores to ACTH deficiency. In addition, Meyers (1998) reports that patients 
with reduced cortisol levels, states such as those with Addison's disease, can present with 
cognitive impairments, particularly memory loss (Meyers, 1998). 
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Neuropsychological Effects of Thyroid Hormones 
TSH, which is released by the anterior pituitary, stimulates the release of thyroid hormones like 
triiodothyronine and thyroxine by the thyroid gland (Beckwith, 2001). Abnormalities in TSH 
levels - such as those caused by a pituitary tumour or its treatment - can lead to abnormal thyroid 
hormone levels, inducing hypo- or hyperthyroidism. 
Hyperthyroidism - the secretion of excess thyroid hormones has been indicated to playa role in 
affective and anxiety disorders, most notably emotional lability and irritability (Beckwith, 2001). 
In a review of the effects of hormones on mood and cognition, Erlanger et al. (1999) report that 
patients with Grave's disease hyperthyroidism in the context of diffuse goiter, ophthalmopathy 
and dermopathy due to an autoimmune disorder often meet the criteria for multiple psychiatric 
diagnoses including major depression, generalized anxiety disorder, panic disorder, hypomania, 
agoraphobia, obsessive-compulsive disorder and obsessive-compulsive personality disorder. The 
authors maintain that the persistent psychiatric feature across numerous studies is the presence of 
anxiety. 
In terms of cognition, it has been proposed that hyperthyroidism increases the sensitivity of 
tissue to catecholamine, a neurotransmitter of profound importance in models of memory and 
attention (Beckwith, 2001). MacCrimmon, Wallace, Goldberg and Streiner (1979) and Wallace, 
MacCrimmon and Goldberg (1980) report that serum T 4 levels of thyrotoxic patients correlated 
with impaired concentration and memory, as measured by the Stroop Test and Wechsler Memory 
Scale. Alvarez, Gomex, Alavez and Navarro (1983) report that thyrotoxic patients performed 
worse than healthy controls on the Tolouse-Pieron Concentration Attention Test. Trzepacz, 
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McCue, Klein, Levey and Greenhouse (1988b) report that ten thyrotoxic patients showed mild 
deficits in attention, memory and complex problem-solving. 
Hypothyroidism too has been associated with neuropsychological dysfunction in both the 
psychiatric and cognitive arenas. Psychiatric symptoms associated with hypothyroidism include 
depression, emotional lability and less often, psychoses (Beckwith, 2001) like paranoia and 
psychotic ideation (Erlanger et aI., 1999). Whybrow, Prange and Treadway (1969) reported that 
patients with hypothyroidism performed worse than patients who were thyrotoxic on the Trail 
Making and Porteus Mazes tests, demonstrating impaired attention and problem-solving. An 
important criticism of the study is that hypothyroid patients' performance was not compared with 
that of healthy controls, meaning that no standard baseline was ever set up. In a large-scale 
study, Osterweil, Syndulko, Cohen et al. (1992) compared 54 hypothyroid patients with 30 age-
matched euthyroid controls and found that they performed significantly more poorly on the Mini 
Mental State Exam, copying a cube, the Inglis Paired Associates Leaming Test, the Animal 
Naming Test and Trails Part A. Monzani, Guerra, Caraccio et al. (1993) found that patients with 
subclinical hypothyroidism performed worse than healthy controls on Logical Memory, Digit 
Span, Visual Memory, Associative Memory and overall Memory Quotient. 
As to whether cognitive deficits remain once patient is euthyroid, Whybrow et al. (1969) found 
that the hypothyroid deficits they uncovered (attention and problem-solving) persisted after 
patients had returned to a euthyroid state. Osterweil et al. (1992) report that a five month course 
of replacement therapy significantly improved performance on Trails Part A and the Inglis 
Paired Associates Leaming Test but did not improve performance on the Mini Mental State 
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Exam, copying a cube and the Animal Naming Test in previously hypothyroid patients. 
Mennemeier, Gamer and Heilman (1993) report significant ongoing memory impairment in a 63 
year old female patient with primary hypothyroidism following seven months of thyroid 
replacement therapy. The patient's performance was compared with that of healthy controls on 
various memory tests including the Weschler Memory Scale and found abnormal. In another 
single case study, Leentjens and Kappers (1995) report that poor concentration and memory 
remained after treatment in a 43 year old female with primary hypothyroidism. The patient 
continued to perform poorly on neuropsychological tests and complained of difficulty with 
various tasks of daily living after treatment. 
In sum, it may be concluded that hypo- and hyperthyroid states have been associated with 
psychiatric disorders as well as impaired cognitive performance, specifically within the spheres 
of memory, attention and problem-solving. Moreover, there have been reports of these 
impairments persisting even after the patient has returned to a euthyroid state. 
Neuropsychological E.ffects of Gonadotropins and Gonadal Hormones 
The anterior pituitary's two gonadotropic hormones - LH and FSH - stimulate the production of 
gonadal hormones: androgens, estrogens and progestins (Erlanger et aI., 1999). There is evidence 
that gonadotropins have a role in certain cognitive processes. Gordon and Lee (1986) 
administered tests of both visuospatial and verbal functioning to healthy adults and measured 
their FSH, LH and gonadal hormone levels. In both men and women, high levels of FSH were 
associated with poorer performance on vi suo spatial tasks and improved performance on verbal 
tasks. Higher LH levels were associated with improved performance on both the visuospatial and 
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verbal tasks. These results suggest that FSH and LH have independent properties that affect 
cognitive perfonnance in specific ways, although more research is needed in this area. 
Testosterone, the most abundant of the androgens, has been associated with both psychiatric and 
cognitive functioning. Excess testosterone has been linked to dominant and aggressive 
behaviour, disinhibition, attention-seeking, enterprise, resourcefulness and impUlsivity. 
Conversely, low testosterone levels have been associated with passive and dependent behaviour 
(Burman et al., 1998). In line with these findings, testosterone receptors have been localized to 
regions associated with emotion, particularly the amygdala (Deijen et aI., 1996). 
As regards cognition, androgens are thought to influence optimal spatial functioning. Janowsky, 
Oviatt and Orwoll (1994) administered testosterone supplements to older men experiencing age-
related decline in androgen levels and measured their perfonnance on a wide range of 
neuropsychological tests. The supplement significantly improved perfonnance on the Block 
Design subtest of the WAIS-R (Wechsler, 1981) compared with controls. 
Estradiol the primary estrogen - has been the subject of several studies investigating cognition. 
Nonnal estrogen levels have been alleged to account in part for intact memory processes. Studies 
of postmenopausal women, when estradiol levels decline naturally, report that those receiving 
honnone replacement therapy show significant improvement on memory batteries such as the 
Wechsler Memory Scale, with a definite increase on the Logical Memory subtest (Erlanger et al., 
1999). However, it has been proposed that this menopausal memory cognitive decline is 
secondary to executive dysfunction. For instance, postmenopausal women not receiving honnone 
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replacement are reported to exhibit perseverative errors as well as experience difficulty inhibiting 
incorrect responses (Keenan & Soleymani, 2001). 
OBJECTIVES 
As discussed, ineffective research designs and sampling in the latest pituitary studies has meant 
that adenoma patients have not been assessed as an independent sample group prior to treatment. 
The consequence is that the mechanism(s) behind the supposed cognitive deficits have not been 
identified. The South African eontext is such that the protracted interval between diagnosis and 
treatment provides a unique opportunity for neuropsychological assessment prior to intervention, 
meaning that the effects of the tumour itself can be separated from those of its treatment 
Moreover, in no previous study have macro adenoma patients been the focus of investigations. As 
mentioned before, the South African context is unusual in that the proportion of macroadenomas 
encountered within the adenoma patient population is greater than in developed countries. It is 
true that macroadenoma patients have been included in prior neuropsychological research, but as 
with the pre-treatment patients discussed above, these patients have been subsumed in larger 
adenoma sub-groups, and macro adenomas have never been utilized as a means of investigating 
exaggerated adenoma effects, where any potential dysfunction has the best chance to declare 
itself. This is a particularly worthwhile venture in light of the incongruity between prior 
assumptions about adenomas and the new contentious claims. 
Aside from the necessity for theoretical confirmation, it is important that adenoma 
symptomatology be clearly delineated for the sake of earliest possible diagnosis. Pituitary 
tumours are notoriously insidious; particularly the GH-secreting variant with its very gradual 
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course, as well as prolactinomas in men, which do not lead to suggestive amenorrhoea. Also, 
should new knowledge detennine that pituitary adenomas lead to cognitive dysfunction, it would 
be beneficial to fonnalize the particular aspects of the diagnostic and treatment processes to 
which the discipline of neuropsychology could contribute. For instance, cognitive assessment 
might become part of diagnosis so as to document impainnent and its functional implications. 
Likewise, cognitive rehabilitation could fonn part of intervention in order to assist in the 
development of residual cognitive skills. Further to these aspects of clinical utility, the interface 
of neuropsychology and endocrinology is a fascinating, complex domain, which has the potential 
to yield insights into the nature of cognition itself. Research in the area takes a step in the 
direction of increased understanding of the interaction between the honnonal system and 
cognitive functioning. 
The present study was designed to answer firstly the question of whether pituitary 
macroadenomas produce neuropsychological effects, and secondly, whether there is a difference 
in the neuropsychological effects of the two primary modes of treatment for pituitary adenomas, 
namely: 1) trans sphenoidal surgery supplemented with radiotherapy and 2) dopamine agonist 
therapy. 
METHOD 
Sample 
Four groups of patients were examined. A diagrammatic breakdown of participant groupings 
appears in Figure 1. Patients ranged from 20 to 67 years of age (mean 49 years). 21 were female 
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and 19 male. In order to rule out confounding effects of other medical conditions on cognition, 
the following exclusion criteria were set up: previous strokes, additional brain tumours, 
dementia, head trauma with loss of consciousness, primary epilepsy, history of alcohol abuse and 
history of narcotic use. Macroadenomas have been known to cause hydrocephalus by obstructing 
CSF outflow at the third ventricle (Hirsch and Jewkes, 1996). Because the cognitive effects of 
hydrocephalus are well documented (Ogden, 1986) and not the object of investigation here, those 
patients currently presenting with, or having previously been diagnosed with, hydrocephalus 
were excluded from the study. 
10 
Pre-lreabnent 
40 
Participants 
10 
Treale<jWiItt 
Transsphenoidal surgery 
Anti r~rlinfhAnan\l 
Figure 1 Breakdown of Participant Groupings 
10 
Treated with 
drug therapy 
10 
Heallhy 
controls 
A total of 54 patients were interviewed and assessed in full. Of these, 14 were systematically 
excluded prior to the data analysis stage. Four patients were excluded because, despite having 
had a full history taken on assessment, certain medical information came to light with the 
examination of the hospital file that suggested possible compromised cognitive functioning for 
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reasons other than a pituitary tumour. Two of these patients had a history of trauma with loss of 
consciousness, one an additional brain tumour and the last, stroke. Two more patients were 
excluded because independent examination of patient scans with the aid of a radiologist revealed 
- despite macroadenona diagnoses - a meningioma in the first case and a micro adenoma in the 
second. Another patient was excluded when it was decided to extend the time-since-treatment 
criterion to six months for the surgery group, in order to further minimize acute treatment effects. 
An additional six patients were excluded because, despite identifiable as post-treatment, they did 
not qualify for inclusion in either of the two treatment groups. Their intervention schedules were 
unique (for instance, having received both trans sphenoidal and transfrontal surgical procedures), 
and so poor representations of standard pituitary treatment. Finally, a single patient was excluded 
since he was over 70 years of age at the time of assessment, and may ostensibly have been 
affected by natural, age-related cognitive decline. These rigorous expulsions, while undoubtedly 
leading to a smaller study sample, successfully eliminated possible confounding variables that 
may have been mistaken for a relationship between adenomas and cognitive dysfunction. 
Both the Pre-treatment and Surgery/ Radiotherapy Groups consisted entirely of non-functioning 
adenomas. The Medication Group included eight prolactinomas, one dual-secreting adenoma and 
one non-functioning adenoma. The three treatment groups are subdivided according to tumour 
type in Table 1. The groups were not matched according to disease type on account of previous 
findings that tumour aetiology does not impact on cognitive functioning. Guinan et al. (1998) 
regrouped patients in terms of tumour type, rather than treatment type, and reanalyzed 
neuropsychological test data. Analysis of Variance was carried out and revealed no significant 
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difference between the new groupings. Likewise, Grattan-Smith et al. (1992) found that tumour 
type had no statistically significant effect on the neuropsychological tests carried out. 
Tumour Type 
Prolactinoma 
Dual-Secreting 
Pre-treatment Surgery! Radiotherapy Medication 
o 0 8 
o 
10 
o 
10 
Table 1 Tumour type by treatment group 
At the onset of the study, it was decided that only those patients whose first language was 
English would be interviewed, but it soon became apparent that this would result in far too small 
a sample size. For one, South Africa has 11 ofIicial languages and the fact that the study was 
conducted at state hospitals meant that a true cross-section of the population was involved. 
Moreover, because only macroadenoma patients were included (in other words, patients who had 
been diagnosed relatively late in the disease process), participants tended to be the more 
disadvantaged of state patients. Many were from rural areas where English is seldom used and 
had had little education. For these reasons the criterion of English as a first language was relaxed 
to the principle of English fluency. In other words, patients who were proficient enough in 
English to be tested - despite having a mother tongue other than English - were included as well. 
The study did not undertake endocrine testing on the day of assessment due to unavailability of 
resources. Moreover, it was felt that venous sampling would dramatically reduce consent to 
participate. However, the fact that participants were recruited from hospital settings meant that 
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they were being seen regularly by endocrinologists, and that their most recent endocrine levels 
were available for perusal. For each participant, results were obtained of the endocrine test 
performed closest to the neuropsychological testing (either prior to or just following the session). 
17 participants were receiving hormonal replacement therapy. Five patients in each of Pre-
treatment and Surgery! Radiotherapy Groups and three patients in the Medication Group were 
receiving hydrocortisone for adrenal insufficiency_ Of the Pre-treatment, Surgery/ Radiotherapy 
and Medication Groups, five, seven and three patients were receiving thyroxine due to thyroid 
deficiencies. Two patients from each of the Pre-treatment and Medication Groups, and five from 
the Surgery! Radiotherapy Group were receiving either oestrogens, progestogens or androgens 
for sex hormone insufficiency. Treatment groups are subdivided according to hormone 
replacements in Table 2. 
Hormone Replacement 
Hydrocortisone 
Thyroxine 
Oestrogensl Progestogens 
Pre-treatment Surgery! Radiotherapy Medication 
5 5 3 
5 7 3 
1 5 1 
1 1 
Table 2 Hormone replacements by treatment group 
Since, of the three new studies dealing with pituitary irradiation, two convincingly found no 
cognitive effects (Grattan-Smith et aL, 1992; Peace et aL, 1997), the third producing results 
which could reasonably be attributed to the tumour itself (Guinan et al., 1998), for the purposes 
of this study it was decided that there was little theoretical necessity to include an independent 
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irradiation-only sample. This decision was also bred by neurological practice in that radiotherapy 
very rarely acts as a single modality treatment for adenomas, and this is even more factual in the 
case of the larger macroadenomas. What is most commonly the case is combined therapy, with 
an irradiation follow-up to surgical intervention. 
Likewise, recruiting an adequate surgery-only sample would have proven near impossible 
considering that the majority of surgical interventions for macroadenomas aim to debulk the 
mass and! or decompress local structures, before supplementation with radiation therapy. It is for 
this reason that this study includes a single group made up of cases where both surgery and 
radiotherapy have been performed. 
The original intention was to assess two surgical groups: one transsphenoidal and one 
trans frontal. After careful analysis of Groote Schuur Hospital operation files and interviews with 
the primary pituitary surgeon, it became clear that transcranial surgery is more obscure a 
procedure in practice than it appears in the literature. In fact, since 1994 only six transfrontal 
operations were performed for the removal of pituitary adenomas at Groote Schuur, as compared 
with approximately 100 transsphenoidal procedures. Not only would the sample of transcranial 
patients have been too small for adequate population representation, but it was deemed futile to 
investigate the effects of a treatment that is utilized so infrequently vis-a.-vis trans sphenoidal 
surgery. Taking into account that the other most commonly used treatment for pituitary tumours 
is medication, the grouping schema used in this study is accurate and authentic, mimicking real 
treatment applications, and therefore of practical value for practitioners and patients in today's 
medical setting. 
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1) Pre-treatment Group 
Ten patients, recently diagnosed with a pituitary macroadenoma and not yet having undergone 
primary treatment were recruited from the neurosurgery wards of Groote Schuur Hospital and 
Tygerberg Hospital in the Western Cape and Baragwanath Hospital in Gauteng. Five patients 
were on hormone replacement therapy for hypofunction of the pituitary's target glands: the 
adrenals, thyroid and gonads. Five of these were receiving cortisol replacement, five thyroxine, 
one testosterone and one estrogen. 
In order for there to be the adequate opportunity for patients to be referred and assessed, a 
sufficient time interval between diagnosis and treatment was required. It is in the nature of 
medical treatment to be administered far more promptly than surgery post diagnosis. Surgical 
intervention is limited by time and space on an under-resourced surgery ward's waiting list. 
Moreover, while patients are accustomed to taking medication, surgery and brain surgery in 
particular - is often weighed and considered for a certain time before it is consented to. It is for 
these reasons that although both the endocrine and neurosurgery departments of the two Western 
Cape hospitals agreed to refer macro adenoma patients post diagnosis and before treatment, it was 
only the surgery departments that managed to generate patients that fit the requirement for 
sufficient time gap for assessment. This is significant because, as outlined earlier, the type of 
adenoma at presentation in large part influences the type of treatment offered. What this has 
meant for this study is that the pre-treatment group, restricted by the requisite time lapse between 
diagnosis and treatment, consists entirely of patients chosen for surgery rather than the non-
invasive medication option, which is generally the non-functional adenoma. 
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2) Surgery/Radiotherapy Group 
Ten patients, having undergone transsphenoidal surgery to remove a pituitary macroadenoma 
were selected through a review of Groote Schuur Hospital neurosurgery operation files. Three 
patients had undergone repeat transsphenoidal procedures. All surgical patients recruited had 
been treated postoperatively with radiotherapy. Only cases in which the patient's most recent 
surgery and! or radiotherapy took place at least six months prior were selected, so as not to 
contaminate the data with any acute post-treatment effects. The mean time since most recent 
surgery was five years (with a range of nine months to 18 years). The mean time since 
radiotherapy was four years (with a range often months to 11 years). 
3) Medication Group 
Ten patients who had been treated medically for a pituitary macroadenoma were recruited from 
Groote Schuur Hospital's joint pituitary clinic. All patients were currently being treated with! or 
had been treated with a dopamine agonist. In seven cases, the agonist involved was 
bromocriptine with dosage ranging from I.25mg per day to 2.5mg per day (mean 2.25mg per 
day). In two cases, the medication was cabergoline with twice-weekly dosages of Img and 3mg. 
The final participant was receiving pergolide in a daily dose of 200mg. The length of treatment 
to completion or to date of assessment ranged from seven months to 13 years (mean four years). Un
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In order to match any possible circumstantial stress or depression resulting from medical 
diagnoses and hospital admissions - psychological factors which might impact upon test 
performance - Groote Schuur Hospital inpatients were chosen as a control group. Nine patients 
were enlisted from Groote Schuur Hospital's neurology ward, all of which cases in which the 
cerebrum was not implicated, and one case from the orthopedics ward. A list of these patients' 
diagnoses appears in Table 3 below. 
I. Neurofibromatosis 
2. Peripheral Neuropathy 
3. Peripheral Neuropathy 
4. Peripheral Neuropathy 
5. Cervical Spondylotic Myelopathy 
6. Motor Neurone Disease 
7. Motor Neurone Disease 
8. Rheumatoid Arthritis 
9. Spinal Injury 
10. Chronic Osteitis 
Table 3 Confirmed Diagnoses of Control Group Patients 
44 
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Materials 
General Information 
A basic questionnaire was given to all participants surveying date of birth, gender, handedness, 
first language, years of education, nature of most recent employment, subjective estimation of 
own vision, audition and motor functioning, past medical history and current medications. 
Premorbid Functioning 
• Weschler Adult Reading Test (WART) 
Participants were required to read aloud a list of 50 irregular English words. The number of 
words pronounced correctly yielded an estimate of pre morbid intelligence. 
lvlemory and Executive Functions 
The focus was on neuropsychological tests of memory and executive functions, because these 
functions had been alleged to be impaired in patients with pituitary tumours (Grattan-Smith et 
aI., 1992; Guinan et aI., 1998; Peace et aI., 1997; Peace et aI., 1998). The second factor which 
influenced the selection of the two primary domains of testing was a series of consultations with 
neurologists leading to a thorough understanding of the growth patterns of pituitary tumours as 
well as consultations with neurosurgeons and radiologists regarding the surgical and 
radiotherapeutic procedures used in treatment. Normal memory processing and executive 
functioning are dependent on intact frontal and temporal lobes, and these structures are adjacent 
to the pituitary gland, putting them at risk of incidental damage from the adenoma itself: as well 
as from surgical and radiotherapeutic interventions targeting the gland. 
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The first stage in the process of test choice was the selection of comprehensive standardized 
memory and executive functions batteries, from which individual subtests would be selected. To 
this end, the Wechsler Memory Scale - Third Edition (UK adaptation) (WMS_IIIuK) and the 
Delis-Kaplan Executive Function System (D-KEFS) were chosen for their confirmed reliability 
and validity. These batteries are the gold standards of memory and executive functions tests for 
both neuropsychological research and clinical utility. 
Multiple measures were selected within the domains of memory and executive functions so as to 
add accuracy to the interpretation of possible findings. Within the area of memory both verbal 
and visuospatial recollection were assessed, as were immediate and delayed memory and 
capacity for recognition vis-a-vis capacity for recall. Verbal immediate recall was assessed using 
WMS Logical Memory I and WMS Verbal Paired Associates I. Verbal delayed recall was 
established with WMS Logical Memory II and WMS Verbal Paired Associates II. Verbal 
delayed recognition was examined in Logical Memory II. Visual immediate recall was assessed 
using WMS Family Pictures I, and visual delayed recall using WMS Family Pictures II. Visual 
immediate recognition was established with WMS Faces I and visual delayed recognition with 
Faces II. Executive functions were assessed in both the verbal and visual modalities, assessing 
the full range of higher-level functions. The primary verbal executive functions test utilized was 
the D-KEFS Verbal Fluency Test, while the main non-verbal tests were the D-KEFS Trail 
Making Test and the D-KEFS Tower Test. The D-KEFS Colour-Word Interference Test and the 
D-KEFS Twenty Questions Test are unique in that they provide measures of both verbal and 
non-verbal problem-solving skills within the same task. 
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Once the tests had been chosen, the next stage of the materials process involved the scrutiny of 
all test materials for cultural specificity. Where necessary, test items were adapted for the South 
African population so as to minimize cultural bias. This involved simple substitutions rather than 
fundamental changes to the material. These adaptations are listed in Table 4 below. 
Subtest 
WMS Logical Memory I and II 
Modifications 
South London to East London 
High Street to Main Road 
Pounds to Rands 
Liverpool to Durban 
I 
! WMS Verbal Paired Associates I and II Badger to Squirrel 
Table 4 Adaptations to Standardized Tests for the South African Population 
The following tests were employed: 
Memory 
• Logical Memory I and II 
Two short stories are presented orally by the examiner. The participant is required to recall the 
stories immediate(y and after a 25 35 minute delay, as well as answer key questions in a 
tntelfalse format. VIe test measures immediate and delayed verbal recall as well as delayed 
verbal recognition. Six scores were computed: pt Recall Total Score, LM I Recall Total Score, 
LM II Recall Total Score, Recognition Total Score, Learning Slope Calculation and Percent 
Retention Calculation. 
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• Faces I and II 
A series of faces is presented visually by the examiner. The participant is required to recognize 
the faces from twofitrther series immediately and after a 25 - 35 minute delay. The test measures 
immediate and delayed visual recognition. Two scores were computed: F I Recognition Total 
Score and F II Recognition Total Score. 
• Family Pictures I and II 
A series of family photographs is presented visually by the examiner. The participant is required 
to recall information pertaining to the photographs immediately and after a 25 - 35 minute 
delay. The test measures immediate and delayed visual recall. Three scores were computed: FP I 
Recall Total Score, FP II Recall Total Score and Percent Retention Calculation. 
• Verbal Paired Associates I and II 
A series of novel word associations is presented orally by the examiner. The participant is then 
prompted with the first word of each pair, and is required to recall the corresponding word 
immediately and after a 25 - 35 minute delay. The test measures immediate and delayed verbal 
recall. Five scores were computed: 1st Recall Total Score, VPA I Recall Total Score, VPA II 
Recall Total Score, Learning Slope Calculation and Percent Retention Calculation. 
Un
ive
rsi
ty 
of 
Ca
pe
 To
w
Page 49 
Executive Functions 
• Trail-Making Test 
The participant is required to connect numbers and letters in an alternating, ascending 
sequence, The test measures cognitiveflexibility, as well as rule observance. Two scores were 
computed: Completion Time and Total Errors. 
• Verbal Fluency Test 
The participant is required to generate as many words as possible that begin 'with a series of 
designated letters. The test measures spontaneous verbal generation. One score was computed: 
Total Correct. 
• Colour-Word Interference Test 
The participant is required to name dissonant ink c%llrs in 'r1.Jhich colollr names are printed. 
77ze test measures inhibition of overlearned responses, as well as rule observance. Two scores 
were computed: Completion Time and Total Errors. 
• Twenty Questions Test 
The participant is presented with a stimulus page depicting pictures of 30 common objects. The 
participant is required to ask (hefewest number of yes/no questions possible in order to identify 
the llnh.710Wn target object. The test measures abstract thinking. Three scores were computed: 
Initial Abstraction Score, Total Questions Asked and Total Weighted Achievement Score. 
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• Tower Test 
The participant is required to move disks across three pegs in order to build a designated tower. 
The test measures planning as well as rule observance. Three scores were computed: 
Completion Time, Total Achievement Score and Total Rule Violations. 
Procedure 
Each patient's hospital file was examined for the following information: previous medical 
history, endocrine status, !VIRI report, tumour dimensions, tumour type, any postoperative 
complications and current medication. 
Participants were interviewed at outpatient clinics, in neurosurgery wards at the bedside, at 
special appointments in various hospital offices, or in their homes. In each case, care was taken 
to ensure as quiet and undisturbed an environment as possible. Each assessment session lasted 
approximately three hours. The sequence of tests was the same for all participants. Not all 
participants completed all tests, chiefly because of time constraints on the part of these patients. 
The controls group was assessed on the same battery of neuropsychological tests as used in the 
patient groups. Testing was carried out in a standardized manner, as defined by the 
administrations manuals accompanying test materials. Assessments were conducted and marked 
by the author. Un
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Ethics 
The study protocol was approved by the University of Cape Town's department of Psychology, 
Groote Schuur Hospital's Ethics Board, Groote Schuur Hospital's Medical Records department, 
the department head of neurosurgery at Tygerberg Hospital, Tygerberg Hospital's Medical 
Records department, and the department head of neurosurgery at Baragwanath Hospital. All 
participants were handed a consent form prior to testing, which was simultaneously elucidated by 
the assessor. Following this, any participant questions were answered. Written consent was then 
obtained from each participant. 
RESULTS 
All analyses were carried out using the STATISTICA package. Conventional significance levels 
were adopted (p<0.05). According to one-way analysis of variance CANOVA), the four groups 
did not differ in terms of age, years of education or estimated premorbid IQ, as determined by 
the WART. These results are shown in Tables 5 - 7. 
ss 
1314.20 
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r 1 df SS MS F : p 
GROUP 13 591.075 197.025 
. _.... .. -_. 
Error J36 18108.900 1225.247 
Total ,139 18699.975 
Table 6 Results for years of education across groups 
F p 
i 6497 .196817 
Table 7 Results for estimated premorbid IQ across groups 
One-way ANOVA was used to determine group differences on the 27 measures of the nine 
neuropsychological tests. The four groups did not differ significantly on the following 26 
measures of memory and executive functions at the 5% level: LMI Ft Recall Total Score, LMI 
Recall Total Score, LMII Recall Total Score, LMII Recognition Total Score, LMII Learning 
Slope Calculation, LMII Percent Retention Calculation, FI Recognition Total Score, FII 
Recognition Total Score, FPI Recall Total Score, FPII Recall Total Score, FPII Percent 
Retention Calculation, VPAI Ft Recall Total Score, VPAI Recall Total Score, VPAII Recall 
Total Score, VPAII Learning Slope Calculation, VPAII Percent Retention Calculation, Trail 
Making Completion Time, Trail Making Total Errors, Verbal Fluency Total Correct, Colour-
Word Interference Completion Time, Colour- Word Interference Total Errors, Twenty Questions 
Initial Abstraction Score, Twenty Questions Total Questions Asked, Twenty Questions Total 
Weighted Achievement Score. Tower Total Achievement Score and Tower Total Rule Violations. 
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The sole test that yielded a significant difference was the Tower Total Item Completion Time (F 
(3.7276) P = 0.019713). 
F p 
3.7276 .019713 
Table 8 Tower Total Item Completion Time test results 
To examine more closely the significant finding, Tukey's Honestly Significant Differences was 
carried out as a post-hoc inter-item test. Table 10 shows a difference was found between the Pre-
treatment and Medication Groups. The performance favoured that of the Medication Group. 
0.173115 
Table 9 Tukey's Honestly Significance Differences results Un
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In summary, no significant difference was found between the perfonnance of the Pre-treatment, 
Surgery/ Radiotherapy, Medication or Control Groups on twenty-six of the twenty-seven 
neuropsychological measures. The single significant difference favoured the Medication group 
over the Pre-treatment Group in the Tower Item Completion Time test. 
GENERAL DISCUSSION 
This study involved a neuropsychological investigation of 30 patients with pituitary 
macroadenomas with two important questions in mind: 
1) Do discrepancies in memory and executive perfonnance exist between pituitary 
macroadenoma patients and healthy controls? 
and 
2) Do discrepancies in memory and executive perfonnance exist between transsphenoidali 
radiotherapy patients and bromocriptine agonist patients in relation to healthy controls? 
Although a significant difference was found between the Pre-treatment and Medication Groups 
on a single executive test, it is most critical that a further fundamental question be posed: 
3) If differences are found, are these discrepancies of practical significance? Un
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To answer the two original questions, it is evident from the statistical analyses that in all but one 
of the neuropsychological measures, there were no significant differences between the 
perfonnances of the four groups. A single discrepancy did arise in the fonn of the Tower Item 
Completion Time measure between the Pre-Treatment and Medication Groups. It is clear then, in 
answer to the first question that there is no difference in memory and executive perfonnance 
between pituitary macroadenoma patients and healthy controls. In order to satisfy the second 
original question, we must return to the further fundamental question as to the practical 
significance of the single significant finding. 
It is the interests of sound research to interpret statistical findings within meaningful theoretical 
frameworks. Conceptually, from what we understand about the brain, it is a somewhat 
anomalous result if only a single executive function is impaired in the context of otherwise intact 
executive functioning. 
According to the D-KEFS Administration Manual: 
"One sign of a well-trained, experienced examiner is that he or she is not quick to interpret 
low test scores as indicating cognitive deficits. Rather, the experienced clinician first 
comprehensively evaluates whether a cognitive deficit is consistently revealed by several 
test measures that also are designed primarily for evaluating the ability area or are highly 
dependent on that ability for successful perfonnance." 
(p.32) 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
Page 56 
The point is that the single discrepancy did not persist across the 11 tests assessing executive 
functions in their entirety. Executive functions are a complex conglomeration of functions, and 
executive performance is based upon a host of complex and multifactorial processes. Each of the 
11 executive tests, including the Tower Item Completion Time taps a host of fundamental 
higher-level cognitive skills, and there is considerable overlap between them. Given this 
actuality, it is extremely unlikely that the significant finding reflects a broad population 
difference between pre-treatment and medicated pituitary patients, and so another explanation is 
in order. 
This explanation we find in the form of statistical probability. Because the study was primarily 
exploratory in nature, in order to maximize the chance of detecting group differences and 
therefore minimize type II errors, the conventional alpha level of 0.05 was not adjusted using 
Holm's (1979) conservative Bonferoni procedure. The flip-side of this preference for discovery is 
that the probability of type 1 error is increased, with its likelihood of false positive findings. 
Taken together, these two factors are sufficient to discredit the significant finding and conclude 
that in answer to the second original question, neither of the two primary treatment schedules for 
pituitary adenomas appear to be responsible for, or associated with impaired memory or 
executive functioning. 
Cognitive deficits have been previously reported in pituitary patients (Grattan-Smith et ai., 1992; 
Peace et ai., 1997; Guinan et ai., 1998; Peace et ai., 1998) but these studies need to be interpreted 
with caution due to three factors discussed at length, namely 1) their incongruity with all 
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previous work in the genre of pituitary symptomatology, 2) substantial methodological 
shortcomings, some of which violate the validity of the findings, and 3) their discord on basic 
issues such as the nature of and mechanisms responsible for the very cognitive deficits they 
describe. Furthermore, the present study was set up in the South African context, which granted 
two very advantageous research conditions. The first was the time lapse between diagnosis and 
treatment, which allowed sufficient opportunity for full neuropsychological assessment prior to 
intervention, and therefore the investigation of adenoma patients prior to treatment. The second 
was the relatively large proportion of macroadenomas at diagnosis, allowing the study a full 
macro adenoma-only sample and the opportunity to examine a magnified version of adenoma 
effects. These conditions created a context for research that was not afforded to the previous 
pituitary studies. 
Relevant to the question of the applicability of these macroadenoma-specific findings to 
microadenoma patients, the most important consideration is the fact that macro adenomas are so 
designated solely because of their size; their histological features differ in no way from those of 
their smaller counterparts. Moreover, previous work has shown that size of pituitary tumour does 
not impact on memory or executive impairment performance (Grattan-Smith et aL, 1998). 
As has been discussed, the treatment schedule for pituitary adenomas varies depending on 
numerous factors such as endocrine functioning, tumour size, patient age, patient's visual 
symptoms, and so forth. The present study does not support the conception of surgical, 
radiotherapeutic or medical pituitary treatment as a determinant of cognitive functioning, and so 
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cognitive functioning need not be considered a significant variable in the already-complex choice 
of treatment. 
This is not to say that there do not exist any nonspecific psychosocial consequences of dealing 
with a chronic illness like pituitary disease. Counseling for patients and families should be kept 
in mind as possible recommendations to pituitary patients who are experiencing anxiety or 
depression. Issues of adjustment to illness are general and apply to many chronic conditions, as 
do the emotional struggles a family may experience in dealing with a member who has a chronic 
condition. In light of this, neuropsychologists seem well qualified to play an important part in the 
management of pituitary adenomas. 
It must be acknowledged at this point that this was a retrospective study, meaning that patients 
were not interviewed prior to the development of the adenoma. In other words, there is no 
documented assessment measure available, no mark of baseline functioning, with which to 
compare the current pre-treatment assessments. Using a control group of normally functioning 
individuals does its best to establish a measure of expected scores, as do years of education and 
Wart scores, but these are limited in that they are only estimations of patient norms. 
In the same vein, post-treatment groups were not assessed post diagnosis and prior to treatment. 
Time was the most crucial factor contributing to this limitation of study design, so: The gap 
between surgery and radiotherapy stands at approximately six months. The radiotherapy process 
itself takes roughly two months. In addition, in order not to contaminate cognitive performance 
with acute effects of surgery or radiotherapy, a time lapse of six months since most recent 
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surgery and! or radiotherapy was set. If a surgery/ radiotherapy group was to be assessed both 
prior to surgery and following radiotherapy, the data gathering process for a single patient in this 
group would have been no less than fourteen months. Including a discrete group of pre-treatment 
macroadenoma patients acted to establish a measure of expected functioning prior to treatment, 
but once again, these are limited in that they are only estimations of expected pre-treatment 
functioning for the treatment groups. 
The final limitation is relevant to the question of the external validity of these findings. Pituitary 
patients were enrolled on the basis of the absence of confounding cerebral pathologies, namely: 
previous strokes, additional brain tumours, dementia, head trauma with loss of consciousness, 
primary epilepsy, history of alcohol abuse and history of narcotic use. These exclusion criteria 
may well have led to the construction of an 'ultra healthy' group, not accurately reflecting the 
general population of pituitary patients. 
The present study was conducted as an exploration of the findings of a recent series of articles 
associating pituitary tumours and! or their treatment with cognitive dysfunction. These new texts 
were published at the end of a long line of scientific literature that demarcates adenoma 
symptomatology and treatment effects to the realm of the physical. The present study 
demonstrated clearly that pituitary macroadenomas do not lead to cognitive impairment when 
compared with controls. Moreover, neither of the two primary modes of treatment for adenomas 
was associated with cognitive dysfunction relative to controls. These findings support the 
original assumption of the many published pituitary articles and case reports, and corroborate 
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with the prevailing opinion amongst medical professionals, that pituitary tumours do not affect 
cognition or mood. This study provides reassurance for clinicians and pituitary patients. 
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